ArticleBiomicrofluidics2018
Article in Biomicrofluidics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Surface-Engineered Precision Nano-Systems for Targeted Treatment of Huntington's Disease: A Review of Recent Advancements.International journal of nanomedicine · 2026Review
- Review
- Current status, hotspots and frontiers of ion channel-related research in glioblastoma: a bibliometric analysis from 2005 to 2024.Frontiers in oncology · 2025Review
- Evaluation of Drug Blood-Brain-Barrier Permeability Using a Microfluidic Chip.Pharmaceutics · 2024Article
- Review
- Vascularized liver-on-a-chip model to investigate nicotine-induced dysfunction.Biomicrofluidics · 2023Article
- Scorpion venom heat-resistant peptide alleviates mitochondrial dynamics imbalance induced by PMToxicology research · 2023Article
- Non-Invasive, Targeted Nanoparticle-Mediated Drug Delivery across a Novel Human BBB Model.Pharmaceutics · 2023Article
- Organ-On-A-Chip Models of the Blood-Brain Barrier: Recent Advances and Future Prospects.Small (Weinheim an der Bergstrasse, Germany) · 2022Review
- A predictive microfluidic model of human glioblastoma to assess trafficking of blood-brain barrier-penetrant nanoparticles.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Advances in Hydrogel-Based Microfluidic Blood-Brain-Barrier Models in Oncology Research.Pharmaceutics · 2022Review
- Pharmacokinetics of PEGylated Gold Nanoparticles: In Vitro-In Vivo Correlation.Nanomaterials (Basel, Switzerland) · 2022Article
- In Vitro Models of the Blood-Brain Barrier.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Dynamic 3D On-Chip BBB Model Design, Development, and Applications in Neurological Diseases.Cells · 2021Review
- Magnetic Nanoparticles Used in Oncology.Materials (Basel, Switzerland) · 2021Review
- Bioengineered microfluidic blood-brain barrier models in oncology research.Translational oncology · 2021Review
- The CCL2-CCR2 astrocyte-cancer cell axis in tumor extravasation at the brain.Science advances · 2021Article
- Physiological and Pathological Factors Affecting Drug Delivery to the Brain by Nanoparticles.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Review
- Characterizing the Role of Biologically Relevant Fluid Dynamics on Silver Nanoparticle Dependent Oxidative Stress in Adherent and Suspension In Vitro Models.Antioxidants (Basel, Switzerland) · 2021Article
- 3D Self-Organized Human Blood-Brain Barrier in a Microfluidic Chip.Methods in molecular biology (Clifton, N.J.) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The blood-brain barrier (BBB) is the tightest endothelial barrier in humans. Characterized by the presence of tight endothelial junctions and adherens junctions, the primary function of the BBB is to maintain brain homeostasis through the control of solute transit across the barrier. The specific features of this barrier make for unique modes of transport of solutes, nanoparticles, and cells across the BBB. Understanding the different routes of traffic adopted by each of these is therefore critical in the development of targeted therapies. In an attempt to move towards controlled experimental assays, multiple groups are now opting for the use of microfluidic systems. A comprehensive understanding of bio-transport processes across the BBB in microfluidic devices is therefore necessary to develop targeted and efficient therapies for a host of diseases ranging from neurological disorders to the spread of metastases in the brain.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.